BioLineRx Valuation Analysis

Stocks . USA . 
Stock . BioLineRx
BLRX Stock  USD 3.10  -0.25  -7.46%   
BioLineRx is priced without meaningful earnings support — a reading that maps directly to negative margins and limited earnings visibility. BioLineRx trades at 0.72x book value. On a growth-adjusted basis the PEG ratio sits at 0.2.
Above Model Estimate
Today
3.10
The intrinsic value estimate for BioLineRx is based on a 3 months horizon. Negative profit margins (-99.58%) signal ongoing profitability risk influencing market valuation. Extending the time horizon generally improves valuation stability.
0.12
Downside
2.46
Intrinsic Value
7.16
Upside
Current intrinsic value estimate framed by downside and upside probability thresholds.
Target Odds

Valuation Framework, Methodology & Assumptions

BioLineRx is a micro-cap equity in NASDAQ Health Care category. Market multiples reflect competitive positioning. BioLineRx currently trades at P/S of 11.59.

BioLineRx figures are aggregated from periodic company reporting and market reference feeds and normalized across reporting formats. Valuation outputs are model-derived and depend on published assumptions and reference inputs.

The analysis above is generated by quantitative models and is provided for informational and educational purposes only. It does not constitute financial advice, investment recommendations, or an endorsement to buy or sell any security. All investing involves risk, including the possible loss of principal. Consult a qualified financial advisor before making investment decisions. See our Terms of Use for full details.

Financial data referenced in this analysis is derived from publicly available SEC filings, audited financial statements, and third-party market data providers. The intrinsic value estimate is generated by Macroaxis quantitative models that incorporate fundamental analysis, technical indicators, and risk metrics.

The methodology combines multiple analytical inputs:

  • Fundamental analysis - financial statements, profitability ratios, debt structure, and cash flow metrics sourced from SEC filings and public financial reports
  • Technical indicators - historical price patterns, momentum signals, and volatility measures
  • Risk assessment - probability of bankruptcy models, market risk metrics, and downside scenario analysis
  • Peer comparison - relative valuation against industry peers using standardized multiples

Model outputs are refreshed periodically as new financial data becomes available. Past model performance is not indicative of future results. The intrinsic value estimate reflects a point-in-time calculation and should be considered alongside other research and professional advice.

Data sourced from SEC filings (EDGAR), public financial statements, and market data providers.

Editorial review and methodology oversight provided by: Gabriel Shpitalnik, Member of Macroaxis Editorial Board

Growth Indicators

The market case for BioLineRx appears tied more to rebuilding earnings power than to investors paying up for a high-expectation growth profile. That usually means separating cyclical rebound from durable compounding and checking whether better growth is being matched by healthier margins and cash generation.
Common Stock Shares Outstanding4.11 million
Forward Price Earnings93.4579

Popular Tools for BioLineRx Stock analysis

Portfolio ManagerState of the art Portfolio Manager to monitor and improve performance of your invested capitalFundamental AnalysisView fundamental data based on most recent published financial statementsCompetition AnalyzerCompare fundamental indicators side by side for a group of related or unrelated entitiesIdea OptimizerApply mean-variance optimization to pre-computed thematic ideas and evaluate candidate allocationsContent SyndicationQuickly integrate customizable finance content to your own investment portalInstant RatingsDetermine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performanceAnalyst AdviceAnalyst recommendations and target price estimates broken down by several categoriesTransaction HistoryView history of all your transactions and understand their impact on performancePortfolio File ImportQuickly import all of your third-party portfolios from your local drive in csv format
Tools
Analysis
Directory
Company
2026 Macroaxis LLC Made with in San Francisco
Privacy Terms Widgets Feedback
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and conditions page.